IRIS
FRANCHINA, Tindara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.671
EU - Europa 2.698
AS - Asia 1.956
SA - Sud America 769
AF - Africa 60
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 3
Totale 9.164
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.588
SG - Singapore 853
BR - Brasile 684
SE - Svezia 603
IE - Irlanda 585
CN - Cina 526
IT - Italia 309
PL - Polonia 292
HK - Hong Kong 262
FR - Francia 203
DE - Germania 166
UA - Ucraina 119
VN - Vietnam 110
FI - Finlandia 102
GB - Regno Unito 87
RU - Federazione Russa 73
IN - India 50
AT - Austria 45
CA - Canada 35
BE - Belgio 33
AR - Argentina 31
MX - Messico 26
ZA - Sudafrica 23
ID - Indonesia 22
EC - Ecuador 19
IQ - Iraq 19
BD - Bangladesh 18
UZ - Uzbekistan 15
NL - Olanda 14
TR - Turchia 12
JP - Giappone 11
CO - Colombia 10
CZ - Repubblica Ceca 10
ES - Italia 10
PK - Pakistan 10
EE - Estonia 8
JM - Giamaica 7
MA - Marocco 7
VE - Venezuela 7
AL - Albania 6
CI - Costa d'Avorio 6
CL - Cile 6
EU - Europa 6
LT - Lituania 6
NP - Nepal 6
DZ - Algeria 5
KE - Kenya 5
TN - Tunisia 5
AE - Emirati Arabi Uniti 4
BG - Bulgaria 4
DO - Repubblica Dominicana 4
JO - Giordania 4
KZ - Kazakistan 4
LK - Sri Lanka 4
PY - Paraguay 4
CH - Svizzera 3
HR - Croazia 3
IR - Iran 3
KG - Kirghizistan 3
PA - Panama 3
PE - Perù 3
PH - Filippine 3
RS - Serbia 3
UY - Uruguay 3
AO - Angola 2
BO - Bolivia 2
CR - Costa Rica 2
EG - Egitto 2
GA - Gabon 2
GT - Guatemala 2
LV - Lettonia 2
MD - Moldavia 2
NI - Nicaragua 2
NO - Norvegia 2
OM - Oman 2
RO - Romania 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
AM - Armenia 1
AU - Australia 1
AZ - Azerbaigian 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CG - Congo 1
DK - Danimarca 1
GE - Georgia 1
HU - Ungheria 1
IL - Israele 1
IM - Isola di Man 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
ML - Mali 1
MN - Mongolia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
PS - Palestinian Territory 1
Totale 9.161
Salva come PNG Salva come JPEG
Città #
Dublin 583
Chandler 489
Ashburn 448
Dallas 408
Singapore 407
Nyköping 294
Warsaw 283
Hong Kong 262
Jacksonville 241
Beijing 231
New York 127
Messina 121
Los Angeles 108
Ann Arbor 97
The Dalles 96
Dearborn 93
Princeton 93
Medford 82
Cambridge 74
Des Moines 69
São Paulo 48
Buffalo 46
Munich 44
Boardman 41
Vienna 38
Ho Chi Minh City 37
Woodbridge 35
Brussels 33
Pune 26
Tianjin 26
Moscow 25
Dong Ket 24
San Mateo 23
Wilmington 23
Jinan 22
Shenyang 21
Redondo Beach 20
Belo Horizonte 18
Frankfurt am Main 18
Turku 18
Jakarta 17
Lancaster 17
Nanjing 16
Helsinki 15
Johannesburg 15
Rio de Janeiro 15
Stockholm 15
Tashkent 15
Brooklyn 14
Fort Washington 14
Grammichele 14
Brasília 13
Houston 13
Montreal 13
Atlanta 12
Boston 12
Curitiba 12
Hebei 12
London 12
Denver 11
Hanoi 11
San Francisco 11
Nuremberg 10
Porto Alegre 10
Taizhou 10
Campinas 9
Mexico City 9
Paternò 9
Quito 9
Seattle 9
Tokyo 9
Zhengzhou 9
Amsterdam 8
Chennai 8
Chicago 8
Duque de Caxias 8
Düsseldorf 8
Guangzhou 8
Hangzhou 8
Leawood 8
Santa Clara 8
Baghdad 7
Council Bluffs 7
Goiânia 7
Hyderabad 7
Jiaxing 7
Phoenix 7
Toronto 7
Abidjan 6
Bremen 6
Guarulhos 6
Milan 6
Monmouth Junction 6
Ningbo 6
Olomouc 6
Ribeirão Preto 6
Sumaré 6
Auburn Hills 5
Augusta 5
Caratinga 5
Totale 5.774
Salva come PNG Salva come JPEG
Nome #
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives 173
Prognostic value of methlylenetetrahydrofolate reductase (MTHFR), thymidylate synthase (TS) promoter, and p53 codon 72 variants and survival in advanced non-small cell lung cancer (NSCLC). 167
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel 154
Androgen Receptor (AR), E-Cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients 154
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: Two case reports. 150
The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer 143
Activity and safety of gefitinib and erlotinib in metastatic non-small cell lung cancer (NSCLC): A comparative analysis. 136
Androgen receptor (AR), E-cadherin, and Ki-67 as prognostic markers in triple-negative breast cancer (TNBC). 136
Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care. 132
Folate pathway implications in advanced Non Small Cell Lung Cancer (NSCLC): impact of thymidylate synthase (TS) promoter and methlylenetetrahydrofolate reductase (MTHFR) C677T and A1298C variants expression on patients’ outcome and correlation with p53 codon 72 mutations. 127
Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases 124
Nab-paclitaxel and trastuzumab combination: A promising approach for neoadjuvant treatment in HER2-positive breast cancer 124
Can we better manage advanced NSCLC in the elderly with the new therapeutic agents? Preliminary analysis of a real life multicenter study. 121
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review 120
Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: New insights and future perspectives in this complex clinical scenario 120
A new method for titration of oral transmucosal fentanyl citrate (OTFC) starting dose in cancer patients. 118
Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients. 118
Brain metastases in patients with non-small cell lung cancer: focus on the role of chemotherapy. 115
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data 115
Epidermal growth factor receptor (EGFR) G719C mutation as new determinant of long term survival and response in patients with non small cell lung cancer treated with erlotinib: 114
Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer 114
Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer. 113
The palliative role of Gefitinib (Iressa) in the treatment of heavily pretreated patients with advanced, refractory non small cell lung cancer. Results of a 3-year experience. 112
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data. 112
Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer 111
Gefitinib versus Erlotinib treatment in Non Small Cell Lung Cancer (NSCLC): comparison of two clinical experiences. 110
Second-line therapy in advanced non-small cell lung cancer: Cytotoxic agents or tyrosine kinase inhibitors? Our experience. 109
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going 109
Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site 109
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 108
Vaginal Mucosal Melanoma: a Complete Remission after Immunotherapy and '0-7-21' Radiotherapy Regimen (24 Gy/3 fractions/21 days) 108
NSCLC and HER2: between lights and shadows 107
Challenges and promises of physical exercise in advances lung cancer patients 105
Author Correction to: Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy 105
The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy 101
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 100
May the istotype influence the response to pemetrexed in patients with non small cell lung cancer? Preliminary data of our clinical experience. 99
Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database 98
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation 97
Epidermal growth factor receptor (EGFR) G719C mutation as new determinant of long term survival and response in patients with non small cell lung cancer treated with erlotinib: a case report. 96
Predicting sensitivity of non small cell lung cancer to gefitinib and erlotinib: is there still a role for clinical factors ? 96
SAFETY AND ACTIVITY OF ERLOTINIB (TARCEVA) IN HEAVILY PRE-TREATED PATIENTS WITH METASTATIC, REFRACTORY NON SMALL CELL LUNG CANCER 95
Impact of integrated treatments on patient management in solid tumors: From diagnosis to palliative care. 95
Ruolo del Trastuzumab nel Trattamento Adiuvante del Carcinoma Mammario Operabile. 94
Correction: Androgen Receptor (AR), E-cadherin, and Ki-67 as emerging targets and novel prognostic markers in Triple-Negative Breast Cancer (TNBC) patients 94
Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study) 93
Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study. 93
Gefitinib in lung cancer therapy. Clinical results, predictive markers of response and future perspectives. 92
Embolia polmonare 92
Impact of erlotinib on overall survival in non small cell lung cancer patients: is the post progression survival a new paradigm? 92
IL-33/IL-31 axis: A new pathological mechanism for epidermal growth factor receptor tyrosine kinase inhibitors-associated skin toxicity? 92
Emerging targeted therapies for castration-resistant prostate cancer 90
Impact of single-nucleotide polymorphisms in genes coding for folate pathway enzymes on efficacy/toxicity of gemcitabine and pemetrexed based therapy in advanced non small cell lung cancer (NSCLC): new prospectives for old markers. 89
Impact of circulating microRNAs mir-22, mir-24 and mir-34a on response to pemetrexed in patients with non small cell lung cancer 88
Incidence and preferential localizations of bone metastases: biomolecolar and clinical implications. 87
Role of interleukin-23 circulating levels increase in resected colorectal cancer before and after chemotherapy: preliminary data and future perspectives. 87
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study 87
Ruolo del Trastuzumab nel Trattamento Adiuvante del Carcinoma Mammario Operabile 86
Role of Androgen Receptor (AR), Ki 67 and E-cadherin as prognostic markers in Triple Negative Breast Cancer (TNBC) 85
Pegylated liposomal doxorubicin in combination with gemcitabine in elderly women with locally advanced or metastatic breast cancer: safety and activity results of our clinical experience. 85
Molecular and clinical analysis of predictive biomarkers to anti-EGFR inhibitors in metastatic colorectal cancer (mCRC): Interaction among early tumor shrinkage, skin toxicities, and RAS status. 83
Listening understanding and acting (lung): Focus on communicational issue in thoracic oncology 81
Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 79
Safety of the combination Capecitabine plus Bevacizumab in the treatment of heavily treated advanced colorectal cancer patients: Our experience. 78
Neoplasie della testa collo nell’ anziano 78
Role of MTHFR polymorphisms as predictive markers of acute toxicity during 5-fluorouracil based chemotherapy for colorectal cancer: Preliminary data. 77
Safety of trastuzumab, alone or in combination, in elderly patients with HER2-positive breast cancer: A 5-year case series. 76
New biomarkers to predict response to pemetrexed-based chemotherapy in non small cell lung cancer: from 5,10-methylenetetrahydrofolate reductase promises to miRNAs revolution. 76
Safety and clinical activity of trastuzumab (TSM) containing therapies in heavily pretreated patients with metastatic breast cancer (MBC): A five-year experience 75
Ruolo di Trastuzumab nella terapia adiuvante del carcinoma mammario operabile. 74
Turbe della nutrizione: anoressia e cachessia. 74
Temozolamide plus oral vinorelbine in the treatment of brain metastases from solid tumours in heavily pre- treated patients. 71
Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study 71
Rare histotypes of epithelial biliary tract tumors: A literature review 71
Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper 70
Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario 69
Neoplasie della Testa e del Collo nell'anziano 69
POLIMORPHISM OF METHYLENE-TETRAHYDROFOLATE REDUCTASE AND RISK OF LUNG AND COLON-RECTAL CANCER: A CASE CONTROL STUDY 69
Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 68
“Lunga stazionarietà di malattia e clinical benefit con erlotinib in un paziente anziano, forte fumatore, affetto da carcinoma squamoso del polmone”. 65
Safety and activity of trastuzumab (TRA) containing therapies as treatment of metastatic breast cancer(MBC): a five year experience. 64
Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database 63
Use of nivolumab in elderly patients with advanced Non-Squamous NSCLC: results from the Italian Expanded Access Program (EAP) 62
Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System 61
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. 60
Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetings 60
Invecchiamento e cancro. 59
Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System 58
Treatment option for small cell lung cancer: does lanreotide represent a new choice? 57
Immune Checkpoint Inhibitors and the Kidney: A Focus on Diagnosis and Management for Personalised Medicine 56
FGFR a promising druggable target in cancer: Molecular biology and new drugs 54
Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis 52
null 52
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 51
Renal Disorders with Oral Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: An Analysis from the FDA Adverse Event Reporting System Database 49
Re-treatment with gefitinib or treatment with erlotinib after gefitinib failure in responsive non small cell lung cancers: new strategies to overcome acquired resistance. 47
Prediction and validation of GUCA2B as the hub-gene in colorectal cancer based on co-expression network analysis: In-silico and in-vivo study 47
null 40
The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population. 38
Negative Hyperselection in Metastatic Colorectal Cancer for First-Line Anti-EGFR Therapy: A Narrative Review 37
Totale 9.137
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.757
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.757
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021439 0 0 0 0 0 70 63 51 40 95 71 49
2021/2022668 6 71 23 19 28 7 29 27 5 163 90 200
2022/20231.841 128 179 74 157 136 184 49 129 724 9 49 23
2023/2024495 25 80 32 29 23 175 60 4 2 21 8 36
2024/20252.055 34 22 34 112 104 82 57 451 473 156 192 338
2025/20262.231 332 378 474 431 551 65 0 0 0 0 0 0
Totale 9.352